PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–May 28, 2015–
Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, today announced the release of one abstract for X-82 to be presented as a poster during the 2015 American Society for Clinical Oncology (ASCO) annual meeting held in Chicago May 29 through June 2.
X-82 in combination with docetaxel to measure change in vascular parameters and proliferation:
Title: Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel
Poster Session: Saturday, May 30, 8 a.m. – 11:30 a.m., Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics
Abstract Number: TPS2601
Poster Board Number: 317a
Location: S Hall A
Presenter: Justine Bruce, M.D., Carbone Cancer Center, University of Wisconsin, Madison, WI
June 5th: The AI Audit in NYC
Join us next week in NYC to engage with top executive leaders, delving into strategies for auditing AI models to ensure fairness, optimal performance, and ethical compliance across diverse organizations. Secure your attendance for this exclusive invite-only event.
About Tyrogenex
Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1 single agent study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.
In oncology, VEGFR tyrosine kinase inhibitors, such as X-82, typically have demonstrated benefit in a variety of cancers though dosage, and use of this class in combination with other therapies, has been limited by side effects. Phase 1 data show that X-82 could a have a significantly lower toxicity profile, which may make it an ideal candidate for combination therapy.
For ophthalmology, the company has initiated a phase 2 study known as “APEX,” for wet AMD in Previously treated Eylea patients with X-82. The study is designed to evaluate the safety and efficacy of X-82 in the prevention of vision loss due to wet AMD. A phase 1 study showed X-82 was able to maintain or improve vision in all subjects who received the drug for the six-month study duration and most subjects did not require any rescue injections during that time. There were no dose-limiting toxicities encountered during the study.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528006045/en/
Corporate Contact:
Tyrogenex
Teri Swift, 561-727-9559
Corporate Communications
teri@tyrogenex.com
or
Media Contact:
LaVoie Health Science
David Connolly, 617-374-8800 ext. 108
dconnolly@lavoiehealthscience.com
